Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...

"This publication in Gastroenterology reinforces the scientific rigor, statistical significance and clinical impact of the inFoods IBS approach for treating patients,” said Zack Irani-Cohen, CEO of ...

The analyst supported the positive rating with Ojemda’s potential, which is a prescription medicine that treats certain brain ...

The analyst based the rating update on the recent FDA approval of Ojemda (tovorafenib) for BRAF-altered, relapsed, or ...

Arcutis' approvals, growth, and strategic partnerships position it for cash flow breakeven by 2026. Read here for an analysis ...

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ...

Organogenesis' Q1 2025 earnings disappointed, with dominant Advanced Wound Care segment experiencing a sharp revenue decline ...

QuidelOrtho Corporation (NASDAQ:QDEL) has announced a strategic pivot in its molecular diagnostics business, seeking to ...

Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume-exactly where ...

Enveric Biosciences, Inc. (NASDAQ:ENVB) has obtained U.S. Patent No. 12,187,679 for a new family of hydroxylated psilocybin ...

Shares of Cellectar Biosciences Inc (NASDAQ:CLRB) surged 63.5% following the announcement that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its cancer ...

Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following ...